Update for nurse anesthetists: Neuroleptic malignant syndrome

Journal of the American Association of Nurse Anesthetists

Volumn 71, Issue 5, 2003, Pages 389-394

  Waldorf, Steve ^a  

^a St Mary's Hospital Medical Center   (United States)

Author keywords

Malignant; Neuroleptic; Syndrome

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE; CARBIDOPA; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; COCAINE; DANTROLENE; DIAZEPAM; DOPAMINE; DROPERIDOL; FLUPHENAZINE; HALOPERIDOL; LEVODOPA; LITHIUM; LORAZEPAM; METOCLOPRAMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENCYCLIDINE; PROCHLORPERAZINE MALEATE; PROMAZINE; PROMETHAZINE; RISPERIDONE; SUXAMETHONIUM; THIORIDAZINE; TIOTIXENE; UNINDEXED DRUG;

ACUTE INTERMITTENT PORPHYRIA; AUTONOMIC DYSFUNCTION; BASAL GANGLION; BRAIN TUMOR; CATATONIA; CLINICAL EXAMINATION; CONSCIOUSNESS DISORDER; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; DRUG CHOICE; DRUG INTOXICATION; DRUG SAFETY; EARLY DIAGNOSIS; ENCEPHALITIS; EXTRAPYRAMIDAL SYMPTOM; HEAT STROKE; HUMAN; HYPERTHERMIA; HYPOTHALAMUS; MALIGNANT HYPERTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SEPSIS; SEROTONIN SYNDROME; SYNDROME DELINEATION; TETANUS; TETANY; THYROID CRISIS; EDUCATION; METHODOLOGY; NURSE ANESTHETIST; NURSE ATTITUDE; NURSING; ORGANIZATION AND MANAGEMENT; PEROPERATIVE CARE;

ANTIPSYCHOTIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTRAOPERATIVE CARE; NEUROLEPTIC MALIGNANT SYNDROME; NURSE ANESTHETISTS; NURSE'S ROLE; RISK FACTORS;

EID: 0642338684     PISSN: 00946354     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Pearlman CA. Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol. 1986;6:257-273.
2. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185-202.
3. Khan M, Farver D. Recognition, assessment, and management of neuroleptic malignant syndrome. S D J Med. 2000;53:395-400.
4. Velamoor VR. Neuroleptic malignant syndrome: recognition, prevention, and management. Drug Saf. 1998;19:73-82.
5. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth. 2000;85:129-135.
6. Keck PE, Caroff SN, McElroy SL. Neuroleptic malignant syndrome and malignant hyperthermia: end of a controversy? J Neuropsychiatry Clin Neurosci. 1995;7:135-144.
7. Goldfinger SM, Keith SJ, Mrazek DA, et al, eds. Tasman: Psychiatry. Philadelphia, Pa: WB Saunders Co; 1997.
8. Cooke DB, ed. Ellenhorn's Medical Toxicology. 2nd ed. Baltimore, Md: Williams & Wilkins; 1997.
9. Gordon PH, Frucht SJ. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord. 2001;16:960-974.
10. Katzung BG, ed. Basic & Clinical Pharmacology. New York, NY: McGraw-Hill; 2001.
11. Roberts JR. Clinical Procedures in Emergency Medicine. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1998.
12. Barash PG, Cullen BF, Stoelting RK, eds. Clinical Anesthesia. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1997.
13. Yamawaki S, Yanagawa K, Morio M, Mori K. Possible central effect of dantrolene sodium in neuroleptic malignant syndrome [letter]. J Clin Psychopharmacol. 1986;6:378-379.
14. Lazarus A, Mann SC, Caroff SN. The Neuroleptic Malignant Syndrome and Related Conditions. Washington, DC: American Psychiatric Press, Inc; 1989.
15. Addonizio G, Lehmann-Susman V. Neuroleptic Malignant Syndrome: A Clinical Approach. St Louis, Mo: Mosby-Year Book; 1991.
16. Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y. Is the predisposition to neuroleptic malignant syndrome genetically transmitted? Br J Psychiatry. 1991;158:850-853.
17. 2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry. 2001;158:1714-1716.
18. Susman VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q. 2001;72:325-336.
19. Hines-Burnham T, Novak KK, Short RM, Harmon LD, Bell WL, Schweain SL, eds. Drug Facts and Comparisons 2002. St Louis, Mo: Wolters Kluwer Co; 2002.
20. Marx JA, ed. Rosen's Emergency Medicine: Concepts and Clinical Practice. 5th ed. St Louis, Mo: Mosby, Inc; 2002.
21. Goldberg JF. New drugs in psychiatry. Emerg Med Clin North Am. 2000;18:211-231.
22. Velamoor VR. Atypical antipsychotics and neuroleptic malignant syndrome. Can J Psychiatry. 2001;46:865-866.
23. Stoelting RK. Pharmacology and Physiology in Anesthetic Practice. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999.
24. Shaw A, Matthews EE. Postoperative neuroleptic malignant syndrome. Anaesthesia. 1995;50:246-247.
25. Friedman LS, Weinrauch LA, D'Elia JA. Metoclopramide-induced neuroleptic malignant syndrome. Arch Intern Med. 1987;147:1495-1497.
26. Patel P, Bristow G. Postoperative neuroleptic malignant syndrome: a case report. Can J Anaesth. 1987;34:515-518.
27. Pope HG, Keck PE, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986;143:1227-1233.
28. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985;142:1137-1145.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
30. Wong MMC. Neuroleptic malignant syndrome: two cases without muscular rigidity. Aust N Z J Psychiatry. 1996;30:415-421.
31. Behan WMH, Madigan M, Clark BJ, Goldberg J, McLellan DR. Muscle changes in the neuroleptic malignant syndrome. J Clin Pathol. 2000;53:223-227.
32. Martin DT, Swash M. Muscle pathology in the neuroleptic malignant syndrome. J Neurol. 1987;235:120-121.
33. Young CC, Kaufman BS. Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal. J Clin Anesth. 1995;7:652-656.
34. Eles GR, Songer JE, DiPette DJ. Neuroleptic malignant syndrome complicated by disseminated intravascular coagulation. Arch Intern Med. 1984;144:1296-1297.
35. Adityanjee. The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry. 1991; 158:706-707.
36. Goetz CG, Pappert EJ. Textbook of Clinical Neurology. Philadelphia, Pa: WB Saunders Co; 1999.
37. Hermesh H, Aizenberg D, Lapidot M, Munitz H. The relationship between malignant hyperthermia and neuroleptic malignant syndrome [letter]. Anesthesiology. 1989;70:171-172.
38. Longnecker DE, Tinker JH, Morgan GE. Principles and Practice of Anesthesiology. 2nd ed. St Louis, Mo: Mosby-Year Book, Inc; 1998.
39. Caroff SN, Rosenberg H, Fletcher JE, Heiman-Patterson TD, Mann SC. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology. 1987;67:20-25.
40. Morgan GE Jr, Mikhail MS. Clinical Anesthesiology. 2nd ed. New York, NY: McGraw-Hill; 1996.
41. Hurford WE, Bailin MT, Davison JK, Haspel KL, Rosow C, eds. Clinical Anesthesia Procedures of the Massachusetts General Hospital. 5th ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
42. Sakkas P, Davis JM, Hua J, Wang Z. Pharmacotherapy of neuroleptic malignant syndrome. Psychiatric Annals. 1991;21:157-164.
43. Caroff SN, Mann SC, Keck PE. Specific treatment for the neuroleptic malignant syndrome. Biol Psychiatry. 1998;44:378-381.
44. Mann SC, Caroff SN, Bleier HR, Antelo RE, Un H. Electroconvulsive therapy of the lethal catatonia syndrome. Convuls Ther. 1990; 6:239-247.
45. Davis JM, Janicak PG, Sakkas P, Gilmore C, Wang Z. Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther. 1991;7:111-120.
46. Troller JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry. 1999;33:650-650.
47. George AL Jr, Wood CA Jr. Succinylcholine-induced hyperkalemia complicating the neuroleptic malignant syndrome [letter]. Ann Intern Med. 1987;106:172.